The health care burden of skeletal related events in patients with renal cell carcinoma and bone metastasis
- PMID: 24384157
- DOI: 10.1016/j.juro.2013.12.042
The health care burden of skeletal related events in patients with renal cell carcinoma and bone metastasis
Abstract
Purpose: We examined temporal trends in skeletal related events and associated charges in patients with renal cell carcinoma metastatic to bone. We also identified patient and hospital characteristics associated with skeletal related events and related mortality.
Materials and methods: Using the Nationwide Inpatient Sample we abstracted data on patients with renal cell carcinoma who were diagnosed with concomitant bone metastasis between 1998 and 2010. Patients who experienced a skeletal related event were identified and hospital charges were calculated. Multivariate regression models fitted with generalized estimating equations were used to examine predictors of skeletal related events and related in-hospital mortality.
Results: Between 1998 and 2010 a weighted estimate of 144,889 renal cell carcinoma hospital visits of patients with bone metastasis was identified in the Nationwide Inpatient Sample, of which 20.8% involved a skeletal related event. In these cases from 1998 to 2010 the inflation adjusted mean yearly costs associated with hospital admission increased by 207% in 2013 United States dollars (estimated annual percent change 8.94%, p<0.001). Conversely, the rates of skeletal related events and skeletal related event associated mortality decreased significantly (estimated annual percent change -1.11% and -2.9%, respectively, each p<0.001).
Conclusions: The prevalence and in-hospital mortality of skeletal related event associated hospitalization for metastatic renal cell carcinoma is decreasing but such charges to health care in the United States are increasing at an alarming rate. These findings highlight the need for cost-effective treatment strategies to prevent or treat these morbid complications.
Keywords: bone and bones; carcinoma; hospital charges; kidney; neoplasm metastasis; renal cell.
Copyright © 2014 American Urological Association Education and Research, Inc. Published by Elsevier Inc. All rights reserved.
Comment in
-
Kidney cancer: decreased incidence of skeletal-related events in mRCC.Nat Rev Urol. 2014 Apr;11(4):193-4. doi: 10.1038/nrurol.2014.56. Epub 2014 Mar 11. Nat Rev Urol. 2014. PMID: 24619376 No abstract available.
Similar articles
-
Kidney cancer: decreased incidence of skeletal-related events in mRCC.Nat Rev Urol. 2014 Apr;11(4):193-4. doi: 10.1038/nrurol.2014.56. Epub 2014 Mar 11. Nat Rev Urol. 2014. PMID: 24619376 No abstract available.
-
The burden of skeletal-related events in patients with prostate cancer and bone metastasis.Urol Oncol. 2015 Jan;33(1):17.e9-17.e18. doi: 10.1016/j.urolonc.2014.09.010. Epub 2014 Oct 30. Urol Oncol. 2015. PMID: 25443265
-
Economic burden of adverse events in patients with metastatic renal cell carcinoma.Clin Ther. 2013 Dec;35(12):1955-1963.e2. doi: 10.1016/j.clinthera.2013.10.010. Epub 2013 Nov 28. Clin Ther. 2013. PMID: 24290735
-
Skeletal complications in patients with bone metastases from renal cell carcinoma and therapeutic benefits of zoledronic acid.Clin Cancer Res. 2004 Sep 15;10(18 Pt 2):6397S-403S. doi: 10.1158/1078-0432.CCR-040030. Clin Cancer Res. 2004. PMID: 15448038 Review.
-
Cost-effectiveness and reimbursement issues in renal cell carcinoma.Semin Oncol. 1989 Feb;16(1 Suppl 1):20-6. Semin Oncol. 1989. PMID: 2493161 Review.
Cited by
-
Conditional knockout of PDK1 in osteoclasts suppressed osteoclastogenesis and ameliorated prostate cancer-induced osteolysis in murine model.Eur J Med Res. 2023 Oct 13;28(1):433. doi: 10.1186/s40001-023-01425-8. Eur J Med Res. 2023. PMID: 37828580 Free PMC article.
-
Bone metastasis risk and prognosis assessment models for kidney cancer based on machine learning.Front Public Health. 2022 Nov 17;10:1015952. doi: 10.3389/fpubh.2022.1015952. eCollection 2022. Front Public Health. 2022. PMID: 36466509 Free PMC article.
-
Fracture Risk of Long Bone Metastases: A Review of Current and New Decision-Making Tools for Prophylactic Surgery.Cancers (Basel). 2021 Jul 21;13(15):3662. doi: 10.3390/cancers13153662. Cancers (Basel). 2021. PMID: 34359563 Free PMC article. Review.
-
The spinal distribution of metastatic renal cell carcinoma: Support for locoregional rather than arterial hematogenous mode of early bony dissemination.Urol Oncol. 2021 Mar;39(3):196.e9-196.e14. doi: 10.1016/j.urolonc.2020.12.008. Epub 2021 Jan 7. Urol Oncol. 2021. PMID: 33423935 Free PMC article.
-
Radium-223 Dichloride in Combination with Vascular Endothelial Growth Factor-Targeting Therapy in Advanced Renal Cell Carcinoma with Bone Metastases.Clin Cancer Res. 2018 Sep 1;24(17):4081-4088. doi: 10.1158/1078-0432.CCR-17-3577. Epub 2018 May 30. Clin Cancer Res. 2018. PMID: 29848570 Free PMC article. Clinical Trial.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
